Upcoming Webinars

cancel
Showing results for 
Search instead for 
Did you mean: 

Upcoming Webinars

Oligonucleotides (oligos) have become fast-growing modalities in recent years. Along with the development of these candidates has come the increased need for robust analytical methods and easy-to-use data analysis workflows to characterize them. Critical quality attributes of oligos include their mass, purity, and sequence – each of which can be difficult, time consuming, and tedious. As such, software that supports these efforts can be of great value. In this work, we present novel, automated, and integrated software to support these workflows using LC HRAM MS instruments. Purity and sequencing data are presented for a multitude of oligos including antisense, aptamer, and long synthetic samples.   Key Learning Objectives: Techniques for analyzing the critical quality attributes (CQAs) of oligos — including their mass, purity, and sequence How novel, automated, and integrated software can facilitate the analysis of oligo CQAs using LC–HRAM MS instruments. Purity and sequencing data for a multitude of oligos including antisense, aptamer, and long synthetic samples Who Should Attend: Researchers analyzing the critical quality attributes (CQAs) of oligos — including their mass, purity, and sequence Chromatographers Researchers interested in using LC–HRAM MS instruments for determination of oligo mass, purity and sequence Brought to you by: Speakers: Peter Rye Application Engineer Pre Sales, Agilent Technologies Melissa O'Meara Forensic Science Consultant, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Proteolysis-targeting chimeras (PROTACs) are a class of bifunctional molecules which are enabling the development of drugs against targets once considered inaccessible.  PROTACs bring a protein of interest into close-proximity to an E3 ubiquitin ligase, resulting in the degradation of the target protein by the ubiquitin-proteasome system.  The design, synthesis, and optimization of PROTACs can be quite challenging due to their complicated mechanism of action and relatively high molecular weight and size.   This webinar will focus on aspects related to PROTAC discovery and chemistry workflows, such as ligand finding strategies, synthesis optimization, and linker design.  Successful development of bifunctional molecules requires a deep understanding of multiple processes, including biophysical events which dictate induced proximity and how technologies such as DNA-encoded libraries (DEL) can be leveraged to identify binders of target proteins.  These topics will be discussed within the context of PROTAC lead optimization.   Key Learning Objectives: Leveraging DNA-encoded libraries (DEL) to identify binders to target proteins Accelerating the optimization of PROTACs towards preclinical candidate selection PROTAC Discovery and Chemistry Workflows Who Should Attend: Scientists and researchers interested in protein degradation workflows Brought to you by: Speakers: Kris Rutten Director, WuXi AppTec Jason Deng Senior Director, DEL Biology, WuXi AppTec Lei Zhou Executive Director, WuXi AppTec Ann Thayer Contributing Editor, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Proteolysis-targeting chimeras (PROTACs) are a class of bifunctional molecules which are enabling the development of drugs against targets once considered inaccessible.  PROTACs bring a protein of interest into close-proximity to an E3 ubiquitin ligase, resulting in the degradation of the target protein by the ubiquitin-proteasome system.  Due to the complex mechanism of action of PROTACs, developing a clear understanding of structure-activity relationships can be quite challenging.   This webinar will focus on PROTAC biology workflows, such as in vitro screening assays, in vivo testing, and optimization of DMPK properties. Topics will include the best use of biochemical assays to measure binary/ternary complex formation, cell-based assays to assess target engagement and degradation, strategies for enhancing drug delivery and formulation, and PK/PD evaluation of PROTACs in animal models. Key Learning Objectives: PROTAC biology workflows, including in vitro screening assays, in vivo testing, and optimization of DMPK properties Strategies for enhancing drug delivery and formulation PK/PD evaluation of PROTACs in animal models Who Should Attend: Scientists and researchers interested in protein degradation workflows Brought to you by: Speakers: Kris Rutten Director, WuXi AppTec Lingbing Sun Director, Biophysics, WuXi AppTec Dr. Liping Ma Senior Study Director, WuXi AppTec Liang Mao Senior Director, WuXi STA, a WuXi AppTec Company Ann Thayer Contributing Editor, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
The importance of glucuronidation for metabolism of xenobiotics in humans is illustrated by the abundance and broad tissue distribution of the enzymes, the diversity of substrates and reactions catalyzed, and the number of distinctive UGT enzymes and their genetic polymorphisms.   The involvement of UGTs in metabolism of new drug candidates will be presented as it underscores the enzymes’ importance from regulatory and safety perspectives. Basic biochemical characteristics of UGTs will be reviewed and examples of major forms of glucuronides formed in humans will be presented. Distinctive properties of acyl-glucuronides and their significance for drug-drug interactions will be highlighted. Factors contributing to underprediction of UGTs’ in vivo contributions to the metabolism of xenobiotics will also be covered. Laboratory approaches aimed at improving these predictions will be covered, as well.   Key Learning Objectives: Significance of UGT-mediated metabolism in drug development process Consequences of formation of acyl-glucuronides Underprediction of in vivo UGT-mediated metabolism Who Should Attend: Research scientists and drug development leadership aiming for successful IND / NDA submission, needing to meet regulatory requests and expectations, desiring to formulate a development plan that mitigates risks of late-stage failure, or simply wanting to better understand the ADME properties and potential DDI risks of their compound. Brought to you by: Speakers: Maciej Czerwinski, Ph.D. Director of Scientific Consulting, XenoTech Kelly McSweeney Contributing Editor, C&EN Media Group
%7Bd65477d8-61ed-4ce2-8158-71024d849dd2%7D_drug-metabolizing-enzymes
Labels (2)
IR and Raman spectroscopy are well established, mature techniques present nowadays in most analytical laboratories.  However, they do pose several key fundamental limitations. The new breakthrough technique of Sub-micron Optical Photothermal Infrared (O-PTIR) Spectroscopy overcomes the limited spatial resolution of traditional IR microscopy with submicron resolution and the limited sensitivity and fluorescence interference limitations of Raman microscopy.    Furthermore, O-PTIR is able to bring together the complementarity of IR and Raman into a single platform, single measurement for the first time, enables sub-micron, simultaneous IR+Raman microscopy delivering IR and Raman spectra from the same spot, at the same time with the same spatial resolution.    This webinar discusses this novel technique and provides numerous application examples.   Part 1: Introduction & Overview by Dr. Mustafa Kansiz   Overview of current direct IR (FTIR & QCL) and Raman micro spectroscopic techniques and Fluorescence Microscopy  Introduction to Submicron O-PTIR and simultaneous Raman microscopy (IR+Raman) and the benefits of co-located Fluorescence  Various application examples of particulates, materials science and more   Part 2: Review of Environmental Applications by Dr. Andrew Ault Microplastics, environmental   Dr. Ault will present the results of his group's recent publication on an important source of atmospheric particles - Sea Spray Aerosols (SSA).     In this work, they characterize individual SSA particles using new generation submicron simultaneous IR+Raman (O-PTIR) microscopy for organic profiling, combined with EDX for elemental profiling.    Dr. Ault will also talk to his recent research relating to microplastics.   Key Learning Objectives: Understand the principle of operation of O-PTIR for submicron IR spectroscopy Learn about specific applications of submicron simultaneous IR and Raman  How O-PTIR can advance your research goals and increase the impact of your publications  Who Should Attend: Laboratory Directors and Managers   Research Professors and Academics Regional Water Board Researchers Industrial Failure Analysis Engineers Chemical and Polymer Engineers and Scientists Vibrational Spectroscopists   Brought to you by: Speakers: Dr. Mustafa Kansiz Director of Product Management and Marketing, Photothermal Spectroscopy Corp. Dr. Andrew Ault Dow Corning Assistant Professor of Chemistry and Associate Professor of Chemistry, University of Michigan Melissa O'Meara Forensic Science Consultant, C&EN Media Group
%7Bab671527-ca29-4c1c-a8ce-34602cad7e03%7D_OPTIR_Banner_Neuron_1200x630_-Drk_BG
Labels (2)
Synthetic oligonucleotides have become the fast-growing therapeutic modality in recent years and are being increasingly developed for treating a wide range of disease conditions. Along with the development of these therapeutic candidates comes the increased need for reliable analytical methods and easy-to-use data analysis workflows to fully characterize them to ensure the intended efficacy. Thus, reliable and sensitive analytical and preparative methods are required to adequately resolve impurities and establish purity and identity of the intended oligonucleotide product.   In this presentation, we will present the relevant chromatography, mass spectrometry and spectroscopy based analytical strategies to confidently detect, quantify and purify oligonucleotides and their related impurities that can help you meet both the challenges of synthetic oligonucleotide quality assessment, and the productivity needs of your lab.   Key Learning Objectives: Learn about the manufacturing challenges associated with synthetic oligo drugs Learn about the critical quality attributes for complete assessment of synthetic oligonucleotides Learn about the analytical approaches for the confident identification, quantification and purification of synthetic oligonucleotides and the related impurities Who Should Attend: Laboratory managers Chromatographers New product developers Brought to you by: Speakers: Parul Angrish, Ph.D. Director, Biopharma/Pharma Market Melissa O'Meara Forensic Science Consultant, C&EN Media Group
%7Bdf15a012-b388-4749-bb83-9e0b156f255b%7D_AdobeStock_236893140
Labels (2)
Labels (2)
The AssayMAP Bravo is a flexible yet easy-to-use automated micro chromatography-based protein sample preparation platform that leverages packed resin bed cartridges, precision flow control, and preoptimized applications to perform a wide variety of sample preparation workflows required during biotherapeutic development.  We have made several advances that allow the AssayMAP Bravo to address even more of the drug development process.  The system can now use large capacity cartridges, work in 21 CFR part 11 compliant labs, and automatically generate reports detailing the sample preparation steps executed.  These new capabilities enable walkup operation, simplified documentation, and seamless method transfer between labs so projects can be moved forward as quickly as possible.   Key Learning Objectives: Discover how the AssayMAP Bravo makes automated sample preparation accessible to non-automation experts to reduce variability, human error, and manual labor. Learn how new 21CFR part 11 enabling features in the new AssayMAP software enable walkup operation and simplify transfer of assays along the entire biotherapeutic development process, including moving from non-compliant to compliant labs. Find out how documentation has been simplified and enhanced with the new automated report generation feature. See the workflows that are enabled on the AssayMAP platform with new large capacity AssayMAP cartridges. Who Should Attend: Scientists doing biotherapeutic drug development from discovery to pre-clinical work. People involved in quality control and assurance.   People looking to increase reproducibility and throughput.  Scientists doing proteomics and phosphoproteomics research.  Brought to you by:         Speakers: Steve Murphy, Ph.D. Workflows and Applications Manager, Agilent Technologies Catherine Dold Health & Environment Writer, C&EN Media Group
%7B5fbee7bb-6ea3-4070-b215-3c15aa828151%7D_Image
Labels (2)
Tuesday, March 14, 2023
X-ray diffraction (XRD) is a well-established, non-destructive method to characterize the crystal structure and phase composition of powder or bulk materials. Despite being a standard analytical method, there are still many challenges faced in XRD measurements. For example, detecting weak diffraction peaks arising from minor or impurity phases can be difficult as they are often lost in the measurement background. Alternatively, overlapping peaks, as often seen in multi-component samples, can make correct identification of the present phases difficult.     With the recent introduction of XRDynamic 500, an automated multipurpose powder X-ray diffractometer, and the new instrumentation developments that it has brought, improvements to the data quality and instrument usability have been made that mean that these common challenges can now finally be addressed.    Anton Paar is proud to present “4 Key Developments Advancing Powder XRD,” a live webinar discussing the common challenges faced in XRD measurements and how a new generation of instrumentation seeks to address them. Real-world application examples will be presented on various sample types to showcase the benefits of a modern instrument.      Key Learning Objectives: New developments in powder XRD instrumentation that can improve data quality and ease of use  Real-world applications that showcase the added benefits when using state-of-the-art XRD instrumentation  Who Should Attend: Research Scientists  Laboratory Managers  University Researchers  Quality Engineers   Brought to you by: Speakers: Andrew Jones XRD Product Manager, Anton Paar Melissa O'Meara Forensic Science Consultant, C&EN Media Group
%7Bc3f4c135-5c39-4d32-a39d-cbe3ba75d4df%7D_Untitled_design_%2843%29
Labels (2)
Recent news about heavy metals detected in baby food has many parents worried and with many questions. Regulators provide validated methods that food labs can use to analyze heavy metals in food.  Join Agilent and CEM for an educational seminar on the preparation and elemental analysis of baby foods by inductively coupled plasma–mass spectrometry (ICP-MS) using FDA Method EAM 4.7.     Data from a market basket study on store bought baby foods will be presented. CEM will provide tips and techniques to prepare a wide range of baby foods in a single batch including acid selection, vessels, and programs. Agilent will demonstrate elemental analysis by ICP-MS and highlight new software features.   Key Learning Objectives: Review FDA method EAM 4.7 for sample preparation and elemental analysis by ICP-MS Learn how to perform microwave digestion of 40 baby food and food standard reference material (SRM) samples and blanks in a single batch Learn how to best run your ICP-MS for food analysis, and how to have confidence in your data with new software features Who Should Attend: Metals analysis lab managers, chemists, and technicians involved in trace metals testing of foods  Lab managers and lab technicians looking to optimize heavy metals analysis of foods Lab directors and commercial lab managers looking to increase throughput of food sample testing Brought to you by:   Speakers: Jenny Nelson Applications Scientist, Agilent Technologies Elaine Hasty Senior Applications Chemist, CEM Corporation Catherine Dold Health & Environment Writer, C&EN Media Group
%7Bcfdee875-360c-4d06-87d9-c5c599be3880%7D_Heavy-Metals-in-Baby-Food-1200x630
Labels (2)
Computational chemistry offers a fast and innovative approach to drug discovery and is especially powerful when used in combination with biological testing to provide a complete and reliable picture of a target system. Implementing these techniques to the concept of drug repurposing - taking existing drugs already clinically approved for their use in other disease areas and identifying those which show anti-cancer activity – offers a fast-tracked approach to cancer research, easing the strain on time and resources.    Here, we demonstrate the power of this integrated approach through the collaboration between Cresset Discovery and the Drug Discovery and Development Group, University of South Australia. Virtual screening enabled a targeted, high-throughput evaluation of existing compounds, before the most promising molecules were progressed to further cellular studies to identify the anti-viral drug rilpivirine as displaying anti-proliferative actions in cancer cell lines.    Key Learning Objectives: Drug repurposing offers a fast-track approach to drug discovery as considerable information already exists on a drug’s pharmacology and possible toxicity.  Drug repurposing has been greatly facilitated by the emergence of virtual screening, which enables high-throughput evaluation of existing compounds.  Combining computational methods with cell-based studies increases the chance of success by giving a complete picture of target protein-ligand systems.  Who Should Attend: Research chemists and managers working in pharmaceutical and biotechnology, particularly:  Medicinal Chemists Computational Chemists Molecular Modelers Research Managers Heads of Research/Chemistry/R&D/Innovation Drug Discovery Project Manager Bench Scientists Brought to you by:   Speakers: Dr. Martin Slater Director, Discovery Cresset Discovery Richard Head Emeritus Professor in the Division of Clinical and Health Sciences, University of South Australia Catherine Dold Health & Environment Writer, C&EN Media Group
%7B86fa9068-00d7-4dd8-b588-435c7bb7253c%7D_Cresset_webinar_header_image
Labels (2)
3-D printing could be transformative in healthcare by empowering clinicians to quickly create high-quality and affordable custom medical implants, but we need more resins that are biocompatible and can be safely destroyed and absorbed into the body after use. Gene therapies aim to attack disease at the source by inhibiting or correcting the production of problematic proteins BEFORE they have a chance to replicate and require traditional drugs. However, like the resins in additive manufacturing, there are challenges to the body tolerating this new technology, for example rapid renal clearance, inefficient delivery to non-liver organs, and immunogenicity/toxicity.   Polymer scientists are working to develop new technologies to augment and support game-changing treatments like gene therapy and 3-D printed implants so that our bodies can safely tolerate their effects leading to wider use and better outcomes. In this extended webinar from the ACS Division of Polymer Chemistry, Matthew L. Becker of Duke University will outline strategies for synthesizing highly functional oligomeric resins that can be photochemically printed into a variety of structures possessing unique mechanical, chemical and degradation properties, including a number of pre-clinical applications. Then, Ke Zhang of Northeastern University will share how his lab is developing a safe and efficient oligonucleotide delivery technology that addresses non-liver organs, reduces cost, and minimizes off-target effects for gene therapy.   This ACS Webinar is moderated by C. Adrian Figg of Virginia Tech and is co-produced with the ACS Division of Polymer Chemistry.
2023-04-13-stock-600-400px-acsnetwork.jpg
Labels (1)
Labels (1)
Asymmetric catalysis has become an integral part of the science-driven technological revolution in the second half of the 21st century, leading to decreased energy demands, sustainable chemical processes and the realization of “impossible” transformations. Asymmetric catalysis based on chiral transition-metal complexes plays an important role in the synthesis of single-enantiomer drugs, perfumes and agrochemicals. The importance of the field is recognized by two Nobel Prize Awards in 2001 (transition-metal catalysis) and 2021 (organocatalysis).    Asymmetric catalysts are traditionally designed by experimental trial-and-error methods, which are resource-, time- and labor-consuming, and thus extremely expensive. Digital methods offer the opportunity to expedite catalyst design. Until recently, computational chemistry, typically quantum chemical studies, indirectly contributed to asymmetric catalyst design by providing rationalization for the mechanism of generation of chirality. With the development of more advanced methods, algorithms and an included layer of automation, computational catalysis is now providing the possibility for direct asymmetric catalyst design.    In this webinar, we will demonstrate how Schrödinger’s advanced digital chemistry platform can be used to accelerate the direct design and discovery of asymmetric catalysts.     Key Learning Objectives: Learn how to design an asymmetric catalyst with computational chemistry Learn how automated high-throughput simulation workflows enable rapid asymmetric catalyst design Understand the intersection of physics-based and machine learning techniques in asymmetric catalyst design Who Should Attend: Synthetic Chemists Materials Scientists Chemical Engineers Digitization Managers R&D Scientists Designing Novel Catalysts Brought to you by: Speakers: Pavel A. Dub Senior Principal Scientist and Product Manager, Schrödinger Melissa O'Meara Forensic Science Consultant, C&EN Media Group
%7Bc912bc96-7ed1-4688-b43a-dc2c45a676b3%7D_Banner
Labels (2)